A Direct Method for Oxidizing Quinoxaline, Tetraazaphenanthrene, and Hexaazatriphenylene Moieties Using Hypervalent λ^3 -Iodinane Compounds

Ludovic Troian-Gautier,[†] Julien De Winter,[‡] Pascal Gerbaux,[‡] and Cécile Moucheron*^{,†}

[†]Laboratoire de Chimie Organique et Photochimie, Université Libre de Bruxelles, 50 av. F. D. Roosevelt, CP160/08, B-1050 Bruxelles, Belgium

[‡]Mass Spectrometry Research Group, Interdisciplinary Center for Mass Spectrometry, University of Mons (UMons), 23 Place du Parc, B-7000 Mons, Belgium

Supporting Information

ABSTRACT: An efficient oxidation reaction of various electronpoor quinoxaline-core-containing compounds, such as quinoxalines, 1,4,5,8-tetraazaphenanthrenes, and 1,4,5,8,9,12-hexaazatriphenylene, using [bis(trifluoroacetoxy)iodo]benzene is reported. These compounds are converted into the corresponding quinoxalinediones in good to high yields at room temperature using an acetonitrile/water



solvent mixture. This unprecedented reaction should enable the synthesis of a wide variety of compounds useful in several fields of chemistry.

uinones and quinoxalinedione derivatives play important roles in organic chemistry, where they serve as building blocks for novel molecules^{1,2} coordination polymers,^{3,4} and in coordination chemistry.⁵ In medicinal chemistry⁶ they are used for their antibacterial, anti-inflammatory, or antineoplastic effects as in the case of tanshiones,^{7,8} which may be used against bone-resorptive diseases, or β -lapachone, which has significant antitumor activity against various forms of cancer.^{9,10}

Even if quinoxalinediones may be synthesized by condensation of an *o*-phenylenediamine with oxalic acid,¹¹ there is currently no method to oxidize a quinoxaline moiety in good yield. Indeed, when a classical oxidant such as potassium permanganate is used with quinoxaline, the reaction yields only pyrazine-2,3-dicarboxylic acid.¹² Furthermore, when another oxidation reagent such as *m*-CPBA,¹³ hydrogen peroxide,¹⁴ potassium persulfate,¹⁵ or the efficient oxygen-transfer reagent HOF·CH₃CN¹⁶ is used on quinoxaline, the reaction yields only *N*-oxide or *N*,*N'*-dioxide, and no oxidation of the adjacent carbon atom is observed.

Finally, for more elaborated systems, such as 1,4,5,8-tetraazaphenanthrene $(TAP)^{17,18}$ and 1,4,5,8,9,12-hexaazatriphenylene (HAT),^{19,20} the reactions are even more complicated, since these highly electron-withdrawing molecules are very reluctant to be oxidized.

In the course of our investigation of synthetic methodologies for the oxidation of electron-withdrawing molecules, we focused our research on well-known hypervalent iodine derivatives,^{21–23} namely, (diacetoxyiodo)benzene (DIB)²⁴ and [bis(trifluoroacetoxy)iodo]benzene (BTI)^{25,26} (Figure 1). These hypervalent λ^3 compounds have attracted great interest over the past decade because of their high versatility.^{27–29} For instance, they are well-known to oxidize a wide variety of



Figure 1. (Diacetoxyiodo)benzene (DIB) and [bis(trifluoroacetoxy)-iodo]benzene (BTI).

compounds bearing a phenol group.^{30–36} Furthermore, BTI is also used to convert methoxy derivatives into the corresponding quinones³⁷ via oxidative demethylation. These hypervalent iodine compounds also present the advantages of being commercially available, not expensive, and rather easy to synthesize.^{24–26} They have thus been widely used during the past decade and have allowed different groups to synthesize a wide variety of novel molecules.

In this paper, we report the use of [bis(trifluoroacetoxy)iodo]benzene as an oxidant for quinoxaline moieties. This oxidation reaction presents a unique character that has, to the best of our knowledge, never been reported in the literature for this type of structure. This novel oxidation strategy allowed us to convert substituted and unsubstituted quinoxalines, 1,4,5,8tetraazaphenanthrenes, and 1,4,5,8,9,12-hexaazatriphenylene into the corresponding "quinoxalinediones" in high yields at ambient temperature. The efficiency of this reaction is particularly remarkable because oxidation of these electronpoor polyazaaromatic compounds is generally unfeasible.

The study was initiated with attempts to oxidize two hydroxy-1,4,5,8-tetraazaphenanthrene derivatives, **1a** and **2a**.

Received: August 23, 2013 Published: September 26, 2013

The Journal of Organic Chemistry

Using DIB or BTI, we managed to convert both isomers 1a and 2a into the corresponding quinoxalinedione 1b in high yields (Figure 2). The structure of this reaction product is in perfect



Figure 2. Oxidation of 1,4,5,8-tetraazaphenanthrene hydroxy derivatives using DIB and BTI.

agreement with the reported literature on phenolic oxidation using the λ^3 hypervalent iodine compounds, where phenol compounds yield the corresponding quinones.

In contrast, when BTI was used on the methoxy derivatives **3a** and **4a**, the product obtained after reaction surprisingly corresponded to an oxidation of the unsubstituted quinoxaline core (Figure 3). This result suggests that the moiety sensitive



Figure 3. Oxidation of 1,4,5,8-tetraazaphenanthrene methoxy derivatives using BTI.

toward BTI oxidation is the quinoxaline core and not the methoxy substituent, as already reported in the literature for other methoxy derivatives.³⁷ Comparatively, no reaction occurred when DIB was used instead of BTI.

In order to verify this hypothesis, we investigated the action of BTI and DIB on various unsubstituted quinoxaline-corecontaining compounds (Figure 4), such as quinoxaline (5a), 1,4,5,8-tetraazaphenanthrene (6a, TAP), and 1,4,5,8,9,12hexaazatriphenylene (7a, HAT). Although DIB was in all cases unable to oxidize these molecules, BTI always yielded the corresponding quinoxalinediones in good to high yields, showing that the quinoxaline core is the reactive moiety and that no particular functional group is required for the oxidation to occur. This result is particularly remarkable because these highly electron-poor heterocycles are generally inert toward oxidation. We managed to scale-up the reaction up to 1 g of compounds 5a, 6a, and 7a with no significant change in the reaction yield.

To further extend the scope of this reaction, we used BTI on various quinoxaline and 1,4,5,8-tetraazaphenanthrene compounds. Electron-poor 1,4,5,8-tetraazaphenanthrene was substituted at position 2 or 3 by several functional groups, such as methoxy (**3a**, **4a**, **8a**), chloride (**9a** and **10a**), formyl (**11a**), ethanoloxy (**12a**), and methyl (**13a**) groups (Figure 5). The results showed that in all cases the product formed was the one where the unsubstituted quinoxaline core was oxidized.



Note



Oxidant

BTI

Compound

5a

Figure 4. Oxidation of unsubstituted quinoxaline-core-containing compounds using BTI.



Figure 5. Oxidation of various 1,4,5,8-tetraazaphenanthrene derivatives using BTI.

Regarding quinoxalines, these molecules were substituted at various positions by numerous functional groups, such as halogen [chloride (14a, 15a, 16a), bromide (17a), iodide (18a)], nitro (19a, 20a, 21a, 22a, 23a), hydroxyl (24a, 25a), methoxy (26a, 27a), and methyl (28a). Once again, the results showed that in all cases the oxidation occurred on the quinoxaline core (Figure 6). These results indicate that in quinoxaline core and does not react with the variety of substituents that were used. Nevertheless, if the quinoxaline is substituted by a hydroxyl group on the benzene ring, only phenolic oxidation occurs.^{33,38}

To determine the key parameters required for the oxidation, we investigated the reaction of BTI with several types of system, namely pyrazine, pyridine, pyridine derivatives, and quinoline. The comparison between pyrazine and pyridine moieties should allow a determination of whether the reactive subunit is the pyridinic one or if two nitrogen atoms are required for the oxidation to occur. Comparison of pyrazine/ quinoxaline and pyridine/quinoline derivatives should indicate whether the presence of a second fused aromatic ring is necessary to form the reported oxidation products.

Despite our efforts, the reactions of BTI with pyridine and quinoline derivatives never gave rise to the formation of the expected oxidation products, nor did the reaction with pyrazine. This strongly suggests that two nitrogen atoms and a second



Figure 6. Oxidation of substituted quinoxalines using BTI.

conjugated aromatic ring must be present for the reaction to occur.

In the cases of pyridine derivatives, quinoline derivatives, and pyrazine, the product isolated after the reaction was iodylbenzene (PhIO₂), resulting from hydrolysis of the trifluoroacetate groups or disproportionation of BTI (Figure 7). Even if it is commonly accepted that the hydrolysis of BTI



Figure 7. Hydrolysis reaction of BTI.

produces PhIO, this hydrolysis is generally carried out under alkaline conditions.³⁹ Disproportionation or hydrolysis of BTI leading to PhIO₂ was confirmed by high-resolution mass spectrometry, infrared spectroscopy, and ¹H and ¹³C NMR data, which are in agreement with the reported chemical shifts.⁴⁰ Furthermore, we also verified that this hydrolysis product was not the oxidative species, confirming therefore that BTI is the real oxidative species in the BTI-mediated quinoxaline oxidation.

Thus, comparison of the results obtained with pyrazine and quinoxaline derivatives indicates that even if two nitrogen atoms are required for this particular oxidation, only compounds containing at least one supplementary fused aromatic ring allow isolation of the expected oxidized products. On the basis of our results, we could propose the following mechanism (Figure 8). First, a nucleophilic attack of one of the nitrogen atom from the quinoxaline core on the iodine atom would take place. This attack would be followed by the addition of water, leading to the hydroxy derivative. This nucleophilic attack by water is most likely favored by the presence of the second nitrogen atom, which decreases even more the electron density on the carbon atom compared with that of the pyridinic core. The second aromatic ring might also stabilize the intermediate. Once the first hydroxy group is present on the molecule, the standard mechanism proposed in the literature for phenolic derivatives would take place.³⁰

The hypothesis concerning this second step is strengthened by the fact that 2- and 3-hydroxy-1,4,5,8-tetraazaphenanthrene **1a** and **2a** yield the same product **1b**, where only phenolic oxidation occurred and no oxidation of the unsubstituted quinoxaline core was observed. If this hypothesis were not correct, we should observe oxidation also in the unsubstituted quinoxaline subunit. In order to confirm the mechanism involving nucleophilic attack by water, an experiment was conducted using $H_2^{18}O$ instead of H_2O . This experiment allowed us to isolate the desired ¹⁸O-enriched quinoxalinedione.

In summary, we have reported the unprecedented use of [bis(trifluoroacetoxy)iodo]benzene as an oxidant toward quinoxaline-core-containing molecules. Oxidation using [bis(trifluoroacetoxy)iodo]benzene was investigated on a wide variety of compounds, such as substituted and unsubstituted quinoxalines, 1,4,5,8-tetraazaphenanthrenes, and 1,4,5,8,9,12-hexaazatriphenylene. This reaction, carried out at room temperature, always yielded the desired quinoxalinedione in good to high yield. When hydroxyl derivatives were used, it was always the phenolic moiety that was oxidized, which is in agreement with literature. The phenolic group is more nucleophilic than the nitrogen atom in the quinoxaline, which probably explains this behavior. This reaction can be scaled-up to a gram of compound with no significant loss in the reaction yield.

EXPERIMENTAL SECTION

General. ¹H NMR and ¹³C NMR spectra were recorded on a 300 MHz spectrometer using DMSO- d_6 as the solvent. Chemical shifts are reported in ppm using the relative solvent peak as a reference standard. The mass spectrometric experiments were performed on a large-scale tandem mass spectrometer having an E1B1E2E3B2E4 geometry, where E stands for an electrostatic sector and B for a magnetic sector. Electron ionization mass spectrometry (EI-MS) was performed by scanning the field of the first magnetic field (B1). The mass-separated ions were counted using an off-axis photomultiplier located after the second electrostatic sector. Accurate mass measurements were recorded using perfluorokerosene (PFK) as the internal calibrant by scanning the accelerating voltage (voltage scan) and increasing the resolution of the mass spectrometer to R = 10 000 at 5% of the peak intensity. The ESI measurements were performed on a QToF2 mass



Figure 8. Proposed mechanism for the quinoxaline-core-containing compounds using BTI.

spectrometer. The HRMS measurements were performed at 10 000 resolution using m/z 322.7782 ions from a NaI solution (10 mg/mL isopropanol/water) as the lock mass. Infrared spectra were recorded in ATR mode on a germanium crystal.

General Procedure for the Oxidation Using (Bisacetoxy)lodobenzene or Bis(Trifluoroacetoxy)lodobenzene. The starting material (0.5 mmol) was dissolved in 15 mL of an acetonitrile/water 3:1 mixture. The mixture was stirred at room temperature, and bis(trifluoroacetoxy)iodobenzene (1.1 mmol) or (bisacetoxy)iodobenzene (1.1 mmol) was then added. The reaction mixture was stirred at room temperature for a period of 24 h. The reaction was monitored using TLC (alumina, CHCl₃/acetone 8:2). If needed, another equivalent of bis(trifluoroacetoxy)iodobenzene was added during the reaction. After completion, the reaction was concentrated under vacuum, and the product was collected by filtration and washed with water, acetonitrile, and diethyl ether. The product was finally dried in a desiccator overnight at room temperature.

Pyrazino[2,3-*f***]quinoxaline-2,3(1***H***,4***H***)-dione (1b). Product 1b was obtained from different starting materials. When hydroxy derivatives 1a and 2a were used, the conversion was achieved using BTI or DIB as the oxidant. When the unsubstituted derivative 6a was used, only BTI allowed the oxidation to occur. The product was obtained as a white solid with yields ranging from 84% to 89% depending on the starting material [1a, 2a, or 6a (89.5–96 mg)]. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 7.67 (d, 1H,** *J* **= 9.0 Hz), 7.83 (d, 1H,** *J* **= 9.0 Hz), 8.93 (dd, 2H,** *J* **= 1.8 Hz), 12.05 (bs, 1H), 12.35 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.7, 155.1, 144.4, 138.7, 131.5, 124.5, 123.3, 119.9, 119.7. EI(+)-MS** *m/z* **(%): 186 (100) (M⁺ – CO), 214 (58) (M⁺), 158 (58) (M⁺ – 2CO). HRMS (EI, sector instrument)** *m/z***: [M⁺] calcd for C₁₀H₆N₄O₂ 214.0491, found 214.0498. IR (neat) ν_{max}/cm⁻¹: 1680.8, 1360.8.**

8-Methoxypyrazino[2,3-f]quinoxaline-2,3(1*H*,4*H*)-dione (3b). The product was obtained as a white solid with a yield of 69% (84.6 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 4.04 (s, 3H), 7.57 (AB syst, 2H, *J* = 9.0 Hz), 8.60 (s, 1H) 12.07 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.5, 138.6, 136.2, 122.7, 121.2, 120.7, 119.7, 54.0. EI(+)-MS *m/z* (%): 216 (100) (M⁺ - CO), 244 (86) (M⁺). HRMS (EI, sector instrument) *m/z*: [M⁺] calcd for C₁₁H₈N₄O₃ 244.0596, found 244.0589. IR (neat) ν_{max} / cm⁻¹: 1693.4, 1378.6, 1327.5.

9-Methoxypyrazino[2,3-*f*]**quinoxaline-2,3(1***H*,4*H*)-**dione** (4b). The product was obtained as a white solid with a yield of 76% (92.6 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 4.19 (s, 3H), 7.41 (d, 1H, *J* = 9.0 Hz), 7.73 (d, 1H, *J* = 9.0 Hz), 8.53 (s, 1H), 11.96 (bs, 1H), 12.26 (bs, 1H). ¹³C spectra for compound 4b could not be obtained because of the extremely low solubility of this compound in conventional organic solvents. EI(+)-MS *m*/*z* (%): 216 (100) (M⁺ – CO), 244 (70) (M⁺). HRMS (EI, sector instrument) *m*/*z*: [M⁺] calcd for C₁₁H₈N₄O₃ 244.0596, found 244.0589. IR (neat) ν_{max} /cm⁻¹: 1713.1, 1682.17, 1578.0, 1346.8.

Quinoxaline-2,3(1*H*,*4H***)-dione (5b).** Product **5b** was obtained from different starting materials. When hydroxy derivative **24a** was used, the conversion was achieved using BTI or DIB as the oxidant. When the unsubstituted derivative **5a** was used, only BTI allowed the oxidation to occur. The product was obtained as a white solid with yields ranging from 79 to 84% depending on the starting material [**5a** (64.1 mg) or **24a** (68.1 mg)]. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.10 (m, 4H), 11.90 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.1, 125.6, 123.0, 115.1. EI(+)-MS *m/z* (%): 162 (100) (M⁺), 134 (60) (M⁺ - CO), 106 (56) (M⁺ - 2CO). HRMS (EI, sector instrument) *m/z*: [M⁺] calcd for C₈H₆N₂O₂ 162.0429, found 162.0435. IR (neat) ν_{max} /cm⁻¹: 1675.0. **Dipyrazino[2,3-f:2',3'-h]quinoxaline-2,3(1H,4H)-dione (7b).**

Dipyrazino[2,3-f:2',3'-h]quinoxaline-2,3(1H,4H)-dione (7b). The product was obtained as a beige solid with a yield of 91% (121.2 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO- d_6): δ 9.16 (d, 2H, J = 1.8 Hz), 9.17 (d, 2H, J = 1.8 Hz), 12.25 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO- d_6): δ 166.8, 1565, 146.6, 145.3, 127.7, 135.6. EI(+)-MS m/z (%): 238 (100) (M⁺ – CO), 266 (66) (M⁺), 210 (42) (M⁺ – 2CO). HRMS (EI, sector instrument) m/z: [M⁺] calcd for C₁₂H₆N₆O₂ 266.0552, found 266.0553. IR (neat) ν_{max} /cm⁻¹: 1690.6, 1627.4, 1375.8.

8,9-Dimethoxypyrazino[2,3-*f*]quinoxaline-2,3(1*H*,4*H*)-dione (**8b**). The product was obtained as a white solid with a yield of 83% (113.7 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 4.02 (s, 3H), 4.20 (s, 3H), 7.31 (d, 1H, *J* = 9 Hz), 7.48 (d, 1H, *J* = 9 Hz), 11.15 (bs, 1H), 11.85 (bs, 1H). ¹³C spectra for compound **8b** could not be obtained because of the extremely low solubility of this compound in conventional organic solvents. EI(+)-MS *m*/*z* (%): 246 (100) (M⁺ – CO), 274 (100) (M⁺). HRMS (EI, sector instrument) *m*/*z*: [M⁺] calcd for C₁₂H₁₀N₄O₄ 274.0702, found 274.0714. IR (neat) ν_{max} /cm⁻¹: 1720.4, 1677.1, 1352.3.

8-Chloropyrazino[2,3-*f*]quinoxaline-2,3(1*H*,4*H*)-dione (9b). The product was obtained as a pale-yellow solid with a yield of 82% (102.2 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.70 (d, 1H, *J* = 9.0 Hz), 7.77 (d, 1H, *J* = 9.0 Hz), 8.97 (s, 1H), 12.30 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.6, 155.1, 145.6, 144.0, 137.7, 129.8, 125.0, 122.1, 121.1, 120.1. EI(+)-MS *m*/*z* (%): 220 (100) (M⁺ – CO), 248 (62) (M⁺), 192 (46) (M⁺ – 2CO). HRMS (EI, sector instrument) *m*/*z*: [M⁺] calcd for C₁₀H₅N₄O₂Cl 248.0101, found 248.0093. IR (neat) ν_{max}/cm^{-1} : 1682.6, 1379.3, 1141.5.

9-Chloropyrazino[2,3-*f*]quinoxaline-2,3(1*H*,4*H*)-dione (10b). The product was obtained as a yellow solid with a yield of 68% (84.4 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.67 (d, 1H, *J* = 9 Hz), 7.86 (d, 1H, *J* = 9 Hz), 8.94 (s, 1H), 12.07 (bs, 1H), 12.40 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.9, 155.3, 146.5, 144.1, 137.2, 126.1, 123.4, 120.2, 119.5. EI(+)-MS *m/z* (%): 220 (100) (M⁺ – CO), 248 (58) (M⁺), 192 (42) (M⁺ – 2CO). HRMS (EI, sector instrument) *m/z*: [M⁺] calcd for C₁₀H₅N₄O₂Cl 248.0101, found 248.0093. IR (neat) ν_{max}/cm^{-1} : 1730.9, 1369.2, 1128.7.

8-Formylpyrazino[**2**,**3**-*f*]**quinoxaline**-**2**,**3**(1*H*,**4***H*)-**dione** (11b). The product was obtained as a pale-yellow solid with a yield of 92% (111.1 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.80 (d, 1H, *J* = 9.0 Hz), 8.02 (d, 1H, *J* = 9.0 Hz), 9.29 (s, 1H), 10.17 (s, 1H), 12.26 (bs, 1H), 12.50 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 192.5, 155.8, 154.9, 145.1, 141.5, 137.5, 132.6, 127.0, 124.4, 121.3, 119.9. EI(+)-MS *m*/*z* (%): 214 (100) (M⁺ – CO), 242 (52) (M⁺), 158 (48) (M⁺ – 3CO), 186 (46) (M⁺ – 2CO). HRMS (EI, sector instrument) *m*/*z*: [M⁺] calcd for C₁₁H₆N₄O₃ 242.04399, found 242.0435. IR (neat) ν_{max}/cm^{-1} : 1694.8, 1590.6, 1383.1, 875.5.

8-(2-Hydroxyethoxy)pyrazino[2,3-f]quinoxaline-2,3(1*H***,4***H***)-dione (12b).** The product was obtained as a white solid with a yield of 75% (102.6 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 3.80 (m, 2H), 4.72 (m, 2H), 4.88 (t, 1H, *J* = 5.4 Hz), 7.40 (d, 1H, *J* = 9.0 Hz), 7.71 (d, 1H, *J* = 9.0 Hz), 8.51 (s, 1H), 11.95 (bs, 1H), 12.26 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 156.9, 155.7, 155.2, 138.2, 135.2, 128.5, 125.2, 122.9, 118.5, 115.3, 68.8, 59.4. HRMS (EI, sector instrument) *m/z*: [M⁺] calcd for C₁₂H₁₀N₄O₄ 274.0702, found 274.0703. IR (neat) ν_{max}/cm^{-1} : 3091.6, 1695.0, 1320.8, 833.4.

8-Methylpyrazino[2,3-*f*]quinoxaline-2,3(1*H*,4*H*)-dione (13b). The product was obtained as a white solid with a yield of 73% (83.1 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 2.71 (s, 3H), 7.61 (d, 1H, *J* = 9.0 Hz), 7.73 (d, 1H, *J* = 9.0 Hz), 8.85 (s, 1H), 12.05 (bs, 1H), 12.24 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.6, 155.1, 153.2, 145.2, 123.6, 122.5, 119.8, 119.5, 106.8, 21.9. HRMS (EI, sector instrument) *m*/*z*: [M⁺] calcd for C₁₁H₈N₄O₂ 228.0647, found 228.0651. IR (neat) *ν*_{max}/cm⁻¹: 1675.6, 1387.9, 861.2.

The Journal of Organic Chemistry

6-Chloroquinoxaline-2,3(1*H***,4***H***)-dione (14b). The product was obtained as a white solid with a yield of 82% (80.7 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 7.11 (m, 3H), 11.97 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.0, 154.8, 126.9, 126.5, 124.8, 122.6, 116.6, 114.4. EI(+)-MS** *m/z* **(%): 196 (100) (M⁺), 168 (48) (M⁺ – CO). HRMS (EI, sector instrument)** *m/z***: [M⁺] calcd for C₈H₅N₂O₂Cl 196.0039, found 196.0032. IR (neat) \nu_{max}/cm^{-1}: 1691.4, 1392.4.**

5-Chloroquinoxaline-2,3(1*H*,*4H***)-dione (15b).** The product was obtained as a beige solid with a yield of 88% (85.9 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.07 (m, 2H), 7.17 (m, 1H), 11.35 (bs, 1H), 12.06 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.4, 154.8, 127.1, 123.7, 123.4, 122.9, 118.6, 114.2. HRMS (EI, sector instrument) m/z: [M⁺] calcd for C₈H₅N₂O₂Cl 196.0039, found 196.0031. IR (neat) ν_{max}/cm^{-1} : 1674.2, 1394.9.

6,7-Dichloroquinoxaline-2,3(1*H***,4***H***)-dione (16b). The product was obtained as a white solid with a yield of 82% (94.4 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): \delta 7.25 (s, 2H), 12.01 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): \delta 154.7, 126.1, 124.3, 116.0. HRMS (EI, sector instrument)** *m/z***: [M⁺] calcd for C₈H₄N₂O₂Cl₂ 229.9650, found 229.9652. IR (neat) \nu_{max}/ cm⁻¹: 1686.9, 1396.9, 873.1.**

6-Bromoquinoxaline-2,3(1*H***,4***H***)-dione (17b). The product was obtained as a white solid with a yield of 79% (95.0 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 7.05 (m, 1H), 7.25 (m, 2H), 11.97 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.0, 154.8, 127.2, 125.4, 125.2, 117.2, 116.9, 114.2. EI(+)-MS** *m***/***z* **(%): 240 (100) (M⁺), 212 (34) (M⁺ – CO). HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₈H₅N₂O₂Br 239.9534, found 239.9539. IR (neat) ν_{max}/cm⁻¹: 1693.7, 1389.2.**

6-lodoquinoxaline-2,3(1*H***,4***H***)-dione (18b). The product was obtained as a white solid with a yield of 86% (123.5 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): \delta 6.91 (d, 1H,** *J* **= 8.1 Hz), 7.40 (m, 2H), 11.90 (bs, 1H), 11.95 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): \delta 154.9, 131.2, 127.3, 125.5, 122.9, 117.1, 85.8. EI(+)-MS** *m***/***z* **(%): 288 (100) (M⁺), 260 (22) (M⁺ – CO). HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₈H₅N₂O₂I 287.9396, found 287.9401. IR (neat) \nu_{max}/cm^{-1}: 1693.9, 1383.2.**

6-Chloro-7-nitroquinoxaline-2,3(1*H***,4***H***)-dione (19b). The product was obtained as a white solid with a yield of 86% (103.5 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 7.26 (s, 1H), 7.82 (s, 1H), 12.24 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.0, 154.5, 130.9, 125.3, 119.8, 116.7, 112.9. EI(+)-MS** *m***/***z* **(%): 241 (100) (M⁺). HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₈H₄N₃O₄Cl 240.9890, found 240.9882. IR (neat) \nu_{max}/cm^{-1}: 1695.4, 1397.7, 881.5.**

6-Bromo-7-nitroquinoxaline-2,3(1*H***,4***H***)-dione (20b). The product was obtained as a white solid with a yield of 87% (124.2 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 7.43 (s, 1H), 7.79 (s, 1H), 12.22 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.0, 154.6, 142.6, 130.9, 125.7, 119.8, 112.8, 106.9. EI(+)-MS** *m***/***z* **(%): 285 (20) (M⁺), 253 (100) (M⁺ – CO), 207 (42) (M⁺ – CO – NO₂). HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₈H₄N₃O₄Br 284.9385, found 284.9376. IR (neat) \nu_{max}/cm^{-1}: 1694.6, 1396.9, 881.3.**

6-lodo-7-nitroquinoxaline-2,3(1*H***,4***H***)-dione (21b). The product was obtained as a pale-yellow solid with a yield of 93% (154.5 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): \delta 7.68 (s, 1H), 7.75 (s, 1H), 12.17 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): \delta 155.0, 154.6, 146.0, 130.9, 126.4, 126.1, 112.3, 80.2. EI(+)-MS** *m***/***z* **(%): 333 (10) (M⁺), 301 (100) (M⁺ - O₂), 255 (36)**

 $(M^+ - O_2 - NO_2)$. HRMS (EI, sector instrument) m/z: $[M^+]$ calcd for $C_8H_4N_3O_4I$ 332.9247, found 332.9233. IR (neat) ν_{max}/cm^{-1} : 1691.9, 1395.1.

6-Nitroquinoxaline-2,3(1*H***,4***H***)-dione (22b). Product 22b was obtained from different starting materials. When hydroxy derivative 25a** was used, the conversion was achieved using BTI or DIB as the oxidant. When the unsubstituted derivative **22a** was used, only BTI allowed the oxidation to occur. The product was obtained as a pale-yellow solid with yields ranging from 77 to 82% depending on the starting material [**22a** (80.6 mg) or **25a** (85.1 mg)]. ¹H NMR (300.1 MHz, DMSO-*d*₆): δ 7.26 (d, 1H, *J* = 8.7 Hz), 7.97 (m, 2H), 12.26 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-*d*₆): δ 155.1, 154.7, 142.1, 131.7, 126.1, 118.6, 115.5, 110.3. EI(+)-MS *m/z* (%): 207 (100) (M⁺), 179 (16) (M⁺ - CO). HRMS (EI, sector instrument) *m/z*: [M⁺] calcd for C₈H₅N₃O₄ 207.0280, found 207.0270. IR (neat) ν_{max} /cm⁻¹: 1693.3, 1337.7.

5-Chloro-6-nitroquinoxaline-2,3(1*H***,4***H***)-dione (23b). The product was obtained as a pale-yellow solid with a yield of 85% (101.9 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): \delta 7.19 (d, 1H,** *J* **= 9.0 Hz), 7.82 (d, 1H,** *J* **= 9.0 Hz), 11.70 (bs, 1H), 12.39 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): \delta 155.2, 154.5, 142.3, 130.6, 124.6, 120.1, 113.7, 112.0. HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₈H₄N₃O₄Cl 240.9890, found 240.9891. IR (neat) \nu_{max}/cm⁻¹: 1720.6, 1535.6, 1396.6.**

6-Methoxy-7-nitroquinoxaline-2,3(1*H***,4***H***)-dione (26b). The product was obtained as a yellow solid with a yield of 89% (105.1 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 6.91 (s, 1H), 7.72 (s, 1H), 12.04 (bs, 2H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.3, 154.2, 149.6, 132.8, 131.8, 118.9, 112.5, 99.9, 56.7. EI(+)-MS** *m***/***z* **(%): 237 (20) (M⁺). HRMS (EI, sector instrument)** *m***/***z***: [M⁺] calcd for C₉H₇N₃O₅ 237.0386, found 237.0391. IR (neat) \nu_{max}/cm⁻¹: 1709.3, 1311.0.**

5-Methoxy-6-nitroquinoxaline-2,3(1*H***,4***H***)-dione (27b). The product was obtained as a white solid with a yield of 85% (101.2 mg) following the general procedure described for the oxidation using bis(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 6.99 (d, 1H,** *J* **= 9.0 Hz), 7.76 (d, 1H,** *J* **= 9.0 Hz), 11.87 (bs, 1H), 12.28 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.0, 154.9, 141.4, 137.2, 131.4, 121.0, 119.9, 110.4, 62.8. HRMS (EI, sector instrument)** *m/z***: [M⁺] calcd for C₉H₇N₃O₅ 237.0386, found 237.0394. IR (neat) \nu_{max}/cm⁻¹: 1726.6, 1538.8, 1387.8.**

5-Methylquinoxaline-2,3(1*H***,4***H***)-dione (28b). The product was obtained as a white solid with a yield of 90% (79.4 mg) following the general procedure described for the oxidation using bis-(trifluoroacetoxy)iodobenzene. ¹H NMR (300.1 MHz, DMSO-***d***₆): δ 2.34 (s, 3H), 6.93 (m, 1H), 6.99 (m, 2H), 11.22 (bs, 1H), 11.90 (bs, 1H). ¹³C NMR (75.5 MHz, DMSO-***d***₆): δ 155.7, 154.8, 125.5, 124.7, 124.0, 123.9, 122.8, 113.2, 17.2. HRMS (EI, sector instrument)** *m/z***: [M⁺] calcd for C₉H₈N₂O₂ 176.0586, found 176.0592. IR (neat) \nu_{max}/ cm⁻¹: 1679.8, 1396.9.**

ASSOCIATED CONTENT

Supporting Information

General information about spectroscopic apparatus and copies of ¹H, ¹³C, IR, MS, and HRMS spectra for the different compounds when available. This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author

*E-mail: cmouche@ulb.ac.be.

Notes

The authors declare no competing financial interest.

The Journal of Organic Chemistry

ACKNOWLEDGMENTS

The authors thank the Fonds National de la Recherche Scientifique (FRS-FNRS) for financial support. L.T.-G. thanks the Fonds pour la Recherche dans l'Industrie et l'Agriculture (F.R.I.A.) for a Ph.D. fellowship. P.G. (senior research associate) and J.D.W. are grateful to the FRS-FNRS for financial support for the acquisition of the Waters Autospec 6F and for continuing support.

REFERENCES

(1) Lindner, B. D.; Engelhart, J. U.; Märken, M.; Tverskoy, O.; Appleton, A. L.; Rominger, F.; Hardcastle, K. I.; Enders, M.; Bunz, U. H. F. *Chem.—Eur. J.* **2012**, *18*, 4627.

- (2) Shang, X.; Xu, X. J. Heterocycl. Chem. 2010, 47, 72.
- (3) Konidaris, K. F.; Perlepes, S. P.; Aromi, G.; Teat, S. J.; Escuer, A.; Manessi-Zoupa, E. *Inorg. Chem. Commun.* **2008**, *11*, 186.
- (4) Shi, L.; Cai, B.; Huang, G.; Wu, J.-Z.; Yu, Y. Z. Anorg. Allg. Chem. 2011, 637, 306.

(5) Kharisov, B. I.; Méndez-Rojas, M. A.; Garnovskii, A. D.; Ivakhnenko, E. P.; Ortiz-Méndez, U. J. Coord. Chem. 2002, 55, 745.

(6) Asche, C. Mini-Rev. Med. Chem. 2005, 5, 449.

- (7) Lee, J.-S.; Han, S.-Y.; Kim, M. S.; Yu, C.-M.; Kim, M. H.; Kim, S.
- H.; Kim, Y. K.; Kim, B. T. Bioorg. Med. Chem. Lett. 2006, 16, 4733. (8) An, L.-K.; Bu, X.-Z.; Wu, H.-Q.; Guo, X.-D.; Ma, L.; Gu, L.-Q.
- *Tetrahedron* **2002**, *58*, 10315. (9) Li, C. J.; Wang, C.; Pardee, A. B. *Cancer Res.* **1995**, *55*, 3712. (10) Reinicke, K. E.; Bey, E. A.; Bentle, M. S.; Pink, J. J.; Ingalls, S. T.; Hoppel, C. L.; Misico, R. I.; Arzac, G. M.; Burton, G.; Bornmann, W.
- G.; Sutton, D.; Gao, J.; Boothman, D. A. *Clin. Cancer Res.* 2005, 11, 3055. (11) Philips, M. A. J. Chem. Soc. 1928, 2393.
- (12) Jones, R. G.; McLaughlin, K. C.; Organic Syntheses; Wiley: New York, 1963; Collect. Vol. IV, p 824. Jones, R. G.; McLaughlin, K. C. Org. Synth. 1950, 30, 86.
- (13) Nasielski, J.; Heilporn, S.; Nasielski-Hinkens, R.; Geerts-Evrard, F. *Tetrahedron* **1987**, *43*, 4329.
- (14) Cooper, S. M.; Heaney, H.; Newbold, J. A.; Sanderson, W. R. Synlett 1990, 533.
- (15) Mixan, C. E.; Pews, R. G. J. Org. Chem. 1977, 42, 1869.
- (16) Carmeli, M.; Rozen, S. J. Org. Chem. 2006, 71, 5761.
- (17) Case, D. H.; Brennan, J. A. J. Am. Chem. Soc. 1959, 81, 6297.
- (18) Nasielski-Hinkens, R.; Benedek Vamos, M. J. Chem. Soc., Perkin Trans 1 1975, 1229.
- (19) Nasielski-Hinkens, R.; Benedek-Vamos, M.; Maetens, D. J. Heterocycl. Chem. 1980, 17, 873.
- (20) Nasielski-Hinkens, R.; Benedek-Vamos, M.; Maetens, D.; Nasielski, J. J. Organomet. Chem. **1981**, 217, 179.
- (21) Musher, J. I. Angew. Chem.. Int. Ed. Engl. 1969, 8, 54.
- (22) Ladziata, U.; Zhdankin, V. V. ARKIVOC 2006, 2006 (ix), 26.
- (23) Moriarty, R. M. J. Org. Chem. 2005, 70, 2893.
- (24) Hossain, Md. D.; Kitamura, T. Synthesis 2005, 1932.
- (25) Page, T. K.; Wirth, T. Synthesis 2006, 3153.
- (26) Hossain, Md. D.; Kitamura, T. Bull. Chem. Soc. Jpn. 2006, 79, 142.
- (27) Zhdankin, V. V.; Stang, P. J. Chem. Rev. 2008, 108, 5299.
- (28) Varvoglis, A. Tetrahedron 1997, 53, 1179.
- (29) Zhdankin, V. V. ARKIVOC 2009, 2009 (i), 1.
- (30) Pelter, A.; Elgendy, S. M. A. Tetrahedron Lett. 1988, 29, 677.
- (31) Pelter, A.; Elgendy, S. M. A. J. Chem. Soc., Perkin Trans. 1 1993, 1891.
- (32) Xu, D.; Penning, T. M.; Blair, I. A.; Harvey, R. G. J. Org. Chem. 2009, 74, 597.
- (33) Barret, R.; Daudon, M. Tetrahedron Lett. 1990, 31, 4871.
- (34) Wu, A.; Duan, Y.; Xu, D.; Penning, T. M.; Harvey, R. G. *Tetrahedron* **2010**, *66*, 2111.
- (35) Kürti, L.; Herczegh, P.; Visy, J.; Simonyi, M.; Antus, S.; Pelter, A. J. Chem. Soc., Perkin Trans. 1 1999, 379.
- (36) Moriarty, R. M.; Prakash, O. Org. React. 2001, 57, 327.

(37) Tohma, H.; Morioka, H.; Harayama, Y.; Hashizume, M.; Kita, Y. Tetrahedron Lett. **2001**, *42*, 6899.

(38) Keinan, S.; Paquette, W. D.; Skoko, J. J.; Beratan, D. N.; Yang, W.; Shinde, S.; Johnston, P. A.; Lazo, J. S.; Wipf, P. Org. Biomol. Chem. **2008**, *6*, 3256.

(39) Saltzman, H.; Sharefkin, J. G. Org. Synth. 1963, 43, 658.

(40) Yusubov, M. S.; Chi, C.-W.; Park, J. Y.; Karimov, R.; Zhdankin, V. V. Tetrahedron Lett. 2006, 47, 6305.